Rx drug ad: effectiveness claims must be balanced by comparable risk information (502(n))

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

In a prescription drug advertisement subject to the section 502(n) brief-summary requirement, if effectiveness information is presented in greater scope, depth, or detail than the brief summary requires, it must be fairly balanced by a comparably substantial presentation of side effects and contraindications. The advertisement is not in violation, however, if the presentation of true side-effect and contraindication information is comparable in depth and detail to the claims made for effectiveness or safety.

Check

In a prescription drug advertisement covered by the 502(n) brief-summary requirement, compare the scope/depth/detail of effectiveness claims to the scope/depth/detail of the side-effects/contraindications presentation. Flag an imbalance (e.g., extensive benefit claims with a comparatively minimal or superficial risk discussion); do not flag if the risk presentation is comparable in depth and detail to the benefit/safety claims.

Escalate when

Whether the risk presentation is "comparable in depth and detail" to the effectiveness claims is a matter of degree requiring human judgment, especially in close cases.

Where this comes from

21 CFR 202.1(e)(5)(ii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…he requirement that it present a “true statement” of information in brief summary relating to side effects, contraindications, and effectiveness if: (i) It is false or misleading with respect to side effects, contraindications, or effectiveness; or (ii) It fails to present a fair balance between information relating to side effects and contraindications and information relating to effectiveness of the drug in that the information relating to effectiveness is presented in greater scope, depth, or detail than is required by section 502(n) of the act and this information is not fairly balanced by a presentation of a summary of true information relating to side effects and contraindications of the drug; Provided, however, That no advertisement shall be considered to be in violation of this section if the presentation of true information relating to side effects and contraindications is comparable in depth and detail with the claims for effectiveness or safety. (iii) It fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the advertisement. (6) Advertisements that are false, lacking in fair balance, or otherwise misleading. An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violativ…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Applies to every piece — the source does not limit its scope.

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Support: the quote is the operative text of 21 CFR 202.1(e)(5)(ii), a binding regulation specifying when an advertisement fails the 502(n) 'true statement' requirement. It is not drawn from an example, definition, or a description of what the rule does not require, and the rule statement's trigger (effectiveness in greater scope/depth/detail than 502(n) requires) and obligation (fair balance by a summary of true side-effect and contraindication information) both appear verbatim in the source.
- Support for the second clause: 'an ad is not violative if risk and benefit presentations are comparable in depth and detail' is the express proviso in the source immediately following the quoted sentence ('Provided, however, That no advertisement shall be considered to be in violation of this section if the presentation of true information relating to side effects and contraindications is comparable in depth and detail with the claims for effectiveness or safety'). It is supported by the source text, but it is not inside the captured quote, so the rule's evidentiary record does not stand on its own for that half of the statement.
- Overstated on scope: 21 CFR 202.1 governs prescription drug advertisements, and (e)(5) specifically qualifies the brief-summary 'true statement' required by section 502(n) of the act. The rule's applies_when is an unqualified 'promotional', which extends the cited authority to promotional labeling (sales aids, detail pieces, leave-behinds) and to non-prescription materials that this section does not reach. The substantive obligation is stated faithfully; only the trigger condition is broader than the source.
- Atomic: the proviso is a qualifier on a single obligation rather than a second independently checkable requirement. The reviewer performs one comparison - relative depth and detail of benefit versus risk presentation.
- Determinism correctly set to judgment: 'fair balance', 'greater scope, depth, or detail', and 'comparable in depth and detail' are all questions of degree that no literal match or presence/absence test can settle. The escalate-when note is consistent with this.
- Authority correctly set to binding: this is a codified federal regulation, not guidance.
- Severity blocker is defensible: an advertisement failing this provision does not satisfy the section 502(n) 'true statement' requirement and is 'lacking in fair balance' under (e)(6), which is a misbranding exposure rather than a stylistic defect.
- Locator 21 CFR 202.1(e)(5)(ii) is correct for the quoted sentence, but it does not cover the proviso that the rule statement's safe-harbor clause relies on.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the operative text of 21 CFR 202.1(e)(5)(ii), which states an advertisement does NOT satisfy the 502(n) 'true statement' requirement if it fails to present fair balance in the manner described. This is binding operative regulatory text, not an example, definition, or preamble commentary, and the rule statement tracks it.
- Not overstated: the rule preserves the conjunctive trigger of the source (effectiveness presented in greater scope/depth/detail than 502(n) requires AND not fairly balanced by a summary of true side-effect/contraindication information) and correctly carries forward the proviso safe harbor ('comparable in depth and detail with the claims for effectiveness or safety'). The 'must be fairly balanced' framing is a fair restatement of a provision whose consequence is failure of the 502(n) true-statement requirement (misbranding), so 'blocker' severity is defensible.
- Atomic: a single fair-balance comparison test; the proviso is an exception to that same test, not a second independently checkable requirement.
- Determinism correctly set to 'judgment': whether a risk presentation is 'comparable in depth and detail' to effectiveness claims turns on degree and adequacy, not presence/absence or literal match. The escalate note is consistent.
- Authority correctly 'binding': 21 CFR 202.1 is a codified regulation implementing FD&C Act 502(n).
- Locator 21 CFR 202.1(e)(5)(ii) is correct and matches the quoted language verbatim.
- Defect: applies_when is empty ({}), which makes the rule facially universal, while the source provision is limited to prescription drug advertisements subject to the section 502(n) brief-summary requirement. The surrounding source text expressly exempts certain advertisements from that requirement (reminder-type advertisements referenced at (e)(2), bulk-sale drug advertisements under (e)(2)(ii), and prescription-compounding drug advertisements under (e)(2)(iii), each containing no therapeutic safety/effectiveness claims). The scoping appears only in the prose statement/check; the structured applicability field is missing this obvious limit and could cause the rule to be fired against OTC materials, labeling, or exempt reminder ads.
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is the operative text of (e)(5)(ii), which states a condition under which an advertisement fails the statutory 'true statement' requirement of section 502(n). The rule statement tracks it closely: effectiveness information presented in greater scope, depth, or detail than the brief summary requires must be fairly balanced by a summary of true side-effect and contraindication information.
- Not overstated: the rule carries the proviso forward verbatim in substance ('not in violation ... if the presentation of true side-effect and contraindication information is comparable in depth and detail to the claims made for effectiveness or safety'), so it does not convert a conditional failure test into an unconditional prohibition, and it does not extend the rule beyond ads subject to (e)(1).
- Atomic: a single balance test plus its own safe harbor, which is part of the same test rather than a second independently checkable requirement.
- Determinism 'judgment' is correct — 'greater scope, depth, or detail' and 'comparable in depth and detail' are matters of degree and balance, which the rule's own escalate-when acknowledges.
- Authority 'binding' is correct: 21 CFR 202.1 is a regulation.
- Severity 'blocker' is defensible: failure of the (e)(5) 'true statement' requirement makes the ad non-compliant with 502(n), and (k) makes non-compliance a misbranding event.
- Locator 21 CFR 202.1(e)(5)(ii) is exactly where the quoted text sits. Empty applies_when is acceptable here because the rule statement itself carries the scope limit ('subject to the section 502(n) brief-summary requirement'), and (e)(1) reaches all prescription-drug advertisements other than the (e)(2) exempt classes — no medium or audience limit exists in the source to add.